Clinical Trial Update: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of HMPL-689 for relapsed/refractory marginal zone lymphoma and follicular lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• HMPL-689

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Marginal Zone Lymphoma, Follicular Lymphoma | Phase 2 | Status: COMPLETED